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Abstract The AMP-activated protein kinase (AMPK) is the
central component of a protein kinase cascade that plays a
major role in energy sensing. AMPK is activated pharmacolog-
ically by 5-amino-4-imidazolecarboxamide (AICA) riboside
monophosphate (ZMP), which mimics the e¡ects of AMP on
the AMPK cascade. Here we show that uptake of AICA ribo-
side into cells, mediated by the adenosine transport system, is
blocked by a number of protein kinase inhibitors. Under these
conditions, ZMP does not accumulate to su⁄cient levels to
stimulate AMPK. Our results demonstrate that careful inter-
pretation is required when using AICA riboside in conjunction
with protein kinase inhibitors to investigate the physiological
role of AMPK.
/ 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The AMP-activated protein kinase (AMPK) plays a major
role in the regulation of energy metabolism and is activated in
response to a rise in the ratio of AMP:ATP, following ATP
depletion [1,2]. AMP increases AMPK activity by direct allo-
steric activation and also by promoting the phosphorylation
of AMPK by an upstream kinase, AMPK kinase (AMPKK).
Recently, several studies have demonstrated that AMPK is
activated by a second mechanism that does not appear to
involve changes in adenine nucleotides, although the molecu-
lar basis for this activation is not understood [3^5]. Once
activated, AMPK plays a diverse role within the cell, switch-
ing-o¡ energy utilising pathways and switching-on energy gen-
erating pathways [2,6]. All of the known functions of AMPK
appear to be aimed at maintaining the energy balance within
the cell, leading to the hypothesis that AMPK acts as a meta-
bolic master switch [7]. For instance, AMPK has been impli-
cated in the increased uptake of glucose [8] and increased fatty
acid oxidation [9] in skeletal muscle following exercise. In
muscle, activation of AMPK by leptin leads to increased fatty
acid oxidation [5]. The combined actions of AMPK make it a
promising target for therapeutic agents aimed at alleviating
the symptoms of metabolic disease states, such as type 2 dia-
betes and obesity. Recently, mutations in the Q2 isoform of
AMPK have been identi¢ed in individuals su¡ering from hy-
pertrophic cardiomyopathy associated with Wol¡^Parkinson^
White syndrome, indicating that the kinase is also important
in the normal development and functioning of the heart
[10,11]. Given the potential role of AMPK in human disease,
considerable e¡ort is being invested by many groups to inves-
tigate further the regulation and function of the kinase.
A major development in AMPK research was the ¢nding
that 5-amino-4-imidazolecarboxamide (AICA) riboside could
be used to activate AMPK pharmacologically in cells [12,13].
AICA riboside is converted in cells to the monophosphate
derivative, ZMP, which can accumulate to high levels, and
mimics the e¡ects of AMP on the AMPK cascade. Until re-
cently, AICA riboside was the only pharmacological activator
of AMPK to be described and many studies investigating the
physiological consequences of AMPK activation relied solely
on its use. Over the last few years several small, cell-permeable
inhibitors of protein kinases have been developed that exhibit
relatively high speci¢city [14]. Zhou et al. reported recently the
identi¢cation of an inhibitor of AMPK [3]. At present this
inhibitor, which they termed compound C, has not been ex-
tensively characterised, but its discovery raises the possibility
of a more selective approach for modulating AMPK activity
in cells. In this study we examined the use of AICA riboside in
conjunction with compound C to modulate AMPK activity in
muscle cells. We report a serious complication that arises with
pharmacological manipulation of AMPK that should be con-
sidered whenever using this approach to investigate the phys-
iological role of the kinase.
2. Materials and methods
2.1. Cell culture
H-2Kb skeletal muscle cells [15] were grown as described previously
[16]. Cells were allowed to di¡erentiate for 4 days prior to treatment.
On the day of harvesting, cells were transferred to 20 mM HEPES,
pH 7.4, 140 mM NaCl, 5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2,
5 mM glucose and incubated for 30 min in the presence or absence of
either 20 WM compound C (a generous gift from Dr. G. Zhou, Merck
Pharmaceuticals), 10 WM SB202190, or 10 WM 203580 (Calbiochem,
San Diego, CA, USA). Inhibitors were dissolved in dimethyl sulph-
oxide and diluted into the cell media to give the appropriate concen-
tration with a ¢nal concentration of 0.2% dimethyl sulphoxide. Cells
were then incubated for a further 30 min in the presence or absence of
either 500 WM AICA riboside, 0.6 M sorbitol or 0.5 mM dinitrophe-
nol (DNP), in the continued presence of inhibitor where added.
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2.2. AMPK activity measurements
Following treatment, cells were lysed in a minimal volume of ice-
cold 50 mM Tris^HCl, pH 7.5, 50 mM NaF, 5 mM Na pyrophos-
phate, 1 mM EDTA, 1 mM dithiothreitol, 10% (v/v) glycerol, 1 mM
benzamidine, 0.1 mM phenylmethane sulphonyl£uoride, 1% (v/v) Tri-
ton X-100 (bu¡er A). Cell debris was removed by centrifugation at
13000Ug for 5 min. AMPK was immunoprecipitated from the lysates
(100 Wg protein) with an anti-L antibody bound to protein-A Sepha-
rose [17]. Immune complexes were washed with 3U1 ml bu¡er A and
AMPK activity determined using the SAMS peptide assay [18].
For in vitro assays AMPK was partially puri¢ed from rat liver, up
to the diethylaminoethyl (DEAE)^Sepharose step [19]. AMPK was
diluted in bu¡er A and assayed using the SAMS peptide in the pres-
ence or absence of varying concentrations of inhibitor. Several dilu-
tions of AMPK were used to ensure the assays were carried out within
a linear range.
2.3. Nucleotide measurements
Nucleotides present in perchloric acid extracts of H-2Kb cells were
analysed by ion-exchange chromatography, as described previously
[4].
2.4. Nucleoside uptake
Adenosine uptake into H-2Kb cells was determined by measuring
the disappearance of [3H]-adenosine (Amersham Biosciences) from the
media [20]. Radiolabelled adenosine (2 WCi/ml) was added to the cells
that had been incubated in the presence or absence of inhibitor for 30
min. Aliquots (40 Wl) of the media were removed after 0, 2, 5, 15 and
30 min and radioactivity remaining in the media determined by scin-
tillation counting.
3. Results
We have previously reported the activation of AMPK in H-
2Kb cells by a number of di¡erent treatments, including
AICA riboside, hyperosmotic stress (0.6 M sorbitol) and
DNP [4,16]. In order to characterise further the physiological
role of AMPK we decided to make use of an inhibitor of the
kinase that has recently been identi¢ed by Zhou and col-
leagues [3]. We were also interested in determining whether
the mechanism of activation of AMPK by hyperosmotic stress
involved the p38 mitogen-activated protein kinase (MAPK).
This pathway is activated in response to hyperosmotic stress
[21] and has been implicated in the AMPK-mediated stimula-
tion of glucose transport [22]. We therefore determined the
e¡ect of compound C (20 WM ¢nal concentration) and two
inhibitors of p38 MAPK, SB202190 (10 WM ¢nal) and
SB203580 (10 WM ¢nal), on the activation of AMPK in H-
2Kb cells in response to either AICA riboside, hyperosmotic
stress or DNP. As can be seen from the results in Fig. 1, all
three kinase inhibitors completely blocked the activation of
AMPK by AICA riboside, but had no signi¢cant e¡ect on
the activation in response to hyperosmotic stress or DNP.
Previous results have demonstrated that compound C inhibits
AMPK in vitro [3], whereas SB202190 and SB203580 have no
e¡ect on AMPK activity [14]. In the present study we con-
¢rmed these previous ¢ndings (data not shown).
Since our results indicated that the inhibitors only blocked
the activation of AMPK by AICA riboside we examined their
e¡ect on the level of ZMP accumulation in H-2Kb cells. Fig. 2
shows the nucleotide pro¢les from cells treated with AICA
riboside in the presence or absence of the inhibitors. All three
inhibitors prevent the accumulation of ZMP that is seen in
control cells incubated with AICA riboside. AICA riboside is
thought to be transported into cells via the adenosine trans-
port system [13]. Therefore, we examined the e¡ect of the
inhibitors on adenosine uptake in H-2Kb cells (Fig. 3). All
Fig. 1. E¡ect of protein kinase inhibitors on AMPK activity in H-
2Kb cells. Cells were incubated in the presence or absence of com-
pound C (20 WM), SB202190 (10 WM) or SB203580 (10 WM) for 30
min prior to the addition of either 500 WM AICA riboside (AI-
CAR), 0.6 M sorbitol or 0.5 mM dinitrophenol (DNP). After a fur-
ther 30 min, cells were lysed and AMPK activity in anti-L immuno-
precipitates measured using the SAMS peptide assay. Results shown
are the mean (P S.E.M) of 3^11 independent measurements and are
plotted as the percentage of activity in control cells incubated in the
absence of inhibitor or activator.
Fig. 2. E¡ect of inhibitors on ZMP accumulation in H-2Kb cells.
Cells were incubated in the presence or absence of either compound
C (20 WM), SB202190 (10 WM) or SB203580 (10 WM) for 30 min be-
fore the addition of 500 WM AICA riboside. After a further 30 min
incubation, cells were lysed by the addition of perchloric acid and
nucleotides analysed by ion-exchange chromatography. The elution
of ZMP, indicated by an arrow, was identi¢ed by co-migration with
a standard. The results shown are representative of two to four in-
dependent experiments.
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three inhibitors signi¢cantly reduced the uptake of radiola-
belled adenosine from the media. As expected, addition of
thymidine (2 mM) competed for uptake of adenosine. Impor-
tantly, AICA riboside (2 mM) also blocked adenosine uptake,
indicating that uptake of this nucleoside is mediated by the
adenosine transport system.
4. Discussion
During the course of our studies on the physiological role
of AMPK we wanted to make use of protein kinase inhibitors
in order to characterise the events upstream and downstream
of AMPK activation. Our initial interest focussed on inhibi-
tion of AMPK itself and inhibition of the p38 MAPK path-
way, which has recently been implicated in the AMPK-medi-
ated activation of glucose transport [22]. Compound C was
recently identi¢ed as an inhibitor of AMPK [3], although to
our knowledge its speci¢city has not been tested extensively.
In contrast, SB202190 and SB203580 are two widely used
inhibitors of p38 MAPK [14]. All three inhibitors blocked
the activation of AMPK by AICA riboside, but had no sig-
ni¢cant e¡ect on AMPK activity in response to hyperosmotic
stress or the mitochondrial uncoupling agent, DNP. These
results are somewhat paradoxical since compound C might
be expected to inhibit AMPK activity under all conditions
whereas SB202190 and SB203580 have no e¡ect on AMPK
activity in vitro (this study and [14]). However, the ¢nding
that all three inhibitors prevent the accumulation of ZMP
following incubation with AICA riboside o¡ers a plausible
explanation for our results. The failure to accumulate ZMP
appears to be due to a reduction in uptake of AICA riboside,
as all three inhibitors signi¢cantly reduced the uptake of ad-
enosine into H-2Kb cells. We have not studied the mechanism
by which the inhibitors reduce nucleoside uptake, although it
seems unlikely that it is due to inhibition of AMPK or p38
MAPK, since SB202190 and SB203580 have no direct e¡ect
on AMPK activity and compound C has no e¡ect on p38
MAPK K or L activity in vitro (A. Woods and D. Carling,
unpublished data). Like most protein kinase inhibitors, the
three compounds we studied act by competing for ATP and
it is possible that the adenosine transport system is sensitive
to this type of mechanism. Whilst we have not determined
whether the inhibition of uptake is due to an e¡ect on trans-
port, or phosphorylation of AICA riboside catalysed by ad-
enosine kinase, what is clear from our results is that ZMP
accumulation is sensitive to protein kinase inhibitors, and
this should be given appropriate consideration wherever ap-
plicable. During the review process of our paper a report from
Huang et al. described the inhibition of nucleoside transport
by p38 MAPK inhibitors [23]. Their results suggest that the
inhibition of uptake of AICA riboside that we observe is
probably due to a direct e¡ect of the protein kinase inhibitors
on nucleoside transport.
Our results also indicate that the e¡ects of compound C are
lost during isolation of AMPK by immunoprecipitation. This
is not surprising since the immune complexes are washed ex-
tensively before measuring AMPK activity. These results do
not preclude the possibility that AMPK activity in situ is
inhibited. Indeed, that this is the case seems likely based on
the results of AMPK activation by metformin in hepatocytes
[3]. In this study, compound C was shown to prevent the
inactivation of acetyl-CoA carboxylase following incubation
with either AICA riboside or metformin. Interestingly, how-
ever, compound C was much less e¡ective in preventing in-
activation of acetyl-CoA carboxylase following incubation
with metformin, suggesting that some of the e¡ect observed
following treatment with AICA riboside may have been due
to a reduction in ZMP accumulation. In another study,
SB203580 was used to implicate p38 MAPK in the AMPK-
mediated increase in glucose transport following activation
with AICA riboside [22]. In this case alternative approaches
were included to demonstrate a role for p38 MAPK in this
response, although the levels of ZMP were not determined.
Over the last few years interest in the AMPK cascade has
grown considerably, to the extent that there is now more than
one paper published on AMPK per week. Many studies in-
vestigating the physiological role of AMPK have relied on the
use of AICA riboside to activate the kinase in animal or cell-
based model systems. As is the case with any study, care must
be taken when interpreting the results obtained from the use
of a pharmacological agent. This point has been made re-
cently for the use of protein kinase inhibitors in the study
of physiological processes [14]. The results of our current
study reveal an important limitation when using AICA ribo-
side in conjunction with protein kinase inhibitors to modulate
AMPK activity. Based on our ¢ndings we would urge inves-
tigators working on AMPK to analyse all their data obtained
with the use of AICA riboside extremely rigorously. Speci¢-
cally, we recommend that the level of ZMP in tissues or cells
incubated with AICA riboside is determined to allow direct
correlation with AMPK activity measurements. It is clear
from the literature that this is often not the case. Secondly,
we suggest that alternative approaches should be used to ac-
tivate AMPK. The recent ¢nding that metformin activates
AMPK [3], by a mechanism that appears to be independent
of changes in adenine nucleotides [4], coupled with the devel-
opment of molecular tools for modulating AMPK activity
[24], makes this a realistic possibility. Implementation of these
basic recommendations will minimise erroneous conclusions
from being made.
Acknowledgements: We would like to thank Drs Gaochao Zhou and
David Moller (Merck Pharmaceuticals, Rahway, NJ, USA) for the
gift of compound C and for their advice with the manuscript. We
thank Angela Woods for help with the p38 MAPK assays. This study
Fig. 3. E¡ect of inhibitors on adenosine uptake. The uptake of ad-
enosine into H-2Kb cells was determined by measuring the rate of
disappearance of [3H]adenosine from the cell culture medium in the
presence or absence of various compounds. The results shown are
the mean values of three to four independent experiments which
varied by less than 10% and are plotted as the percentage of radio-
activity remaining relative to the starting amount (time zero).
FEBS 26667 23-10-02
L.G.D. Fryer et al./FEBS Letters 531 (2002) 189^192 191
was supported by the Medical Research Council (UK) and a project
grant from Diabetes UK (BDA: RD99/0001988).
References
[1] Hardie, D.G. and Carling, D. (1997) Eur. J. Biochem. 246, 259^
273.
[2] Hardie, D.G., Carling, D. and Carlson, M. (1998) Annu. Rev.
Biochem. 67, 821^855.
[3] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody,
J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirsh-
man, M.F., Goodyear, L.J. and Moller, D.E. (2001) J. Clin.
Invest. 108, 1167^1174.
[4] Fryer, L.G., Patel, A.P. and Carling, D. (2002) J. Biol. Chem.
277, 25226^25232.
[5] Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Muller, C.,
Carling, D. and Kahn, B.B. (2002) Nature 415, 339^343.
[6] Kemp, B.E., Mitchelhill, K.I., Stapleton, D., Michell, B.J., Chen,
Z.-P. and Witters, L.A. (1999) Trends Biochem. Sci. 24, 22^25.
[7] Winder, W.W. and Hardie, D.G. (1999) Am. J. Physiol. 277, 1^
10.
[8] Hayashi, T., Hirshman, M.F., Kurth, E.J., Winder, W.W. and
Goodyear, L.J. (1998) Diabetes 47, 1369^1373.
[9] Winder, W.W. and Hardie, D.G. (1996) Am. J. Physiol. 270,
E299^E304.
[10] Blair, E., Redwood, C., Ashra¢an, H., Ostman-Smith, I. and
Watkins, H. (2001) Hum. Mol. Genet. 10, 1215^1220.
[11] Gollob, M.H., Green, M.S., Tang, A.S.L., Gollob, T., Karibe,
A., Hassan, A., Ahmad, F., Lozado, R., Shah, G., Fananapazir,
L., Bachiniski, L.L., Tapscott, T., Gonzales, O., Begley, D., Mo-
hiddin, S. and Roberts, R. (2001) New Engl. J. Med. 344, 1823^
1831.
[12] Sullivan, J.E., Brocklehurst, K.J., Marley, A.E., Carey, F., Carl-
ing, D. and Beri, R.K. (1994) FEBS Lett. 353, 33^36.
[13] Corton, J.M., Gillespie, J.G., Hawley, S.A. and Hardie, D.G.
(1995) Eur. J. Biochem. 229, 558^565.
[14] Davies, S.P., Reddy, H., Caivano, M. and Cohen, P. (2000) Bio-
chem. J. 351, 91^105.
[15] Morgan, J.E., Beauchamp, J.R., Pagel, C.N., Peckham, M., Ata-
liotis, P., Jat, P.S., Noble, M.D., Farmer, K. and Partridge, T.A.
(1994) Dev. Biol. 162, 486^498.
[16] Fryer, L.G., Hajduch, E., Rencurel, F., Salt, I.P., Hundal, H.S.,
Hardie, D.G. and Carling, D. (2000) Diabetes 49, 1978^1985.
[17] Woods, A., Cheung, P.C.F., Smith, F.C., Davison, M.D., Scott,
J., Beri, R.K. and Carling, D. (1996) J. Biol. Chem. 271, 10282^
10290.
[18] Davies, S.P., Carling, D. and Hardie, D.G. (1989) Eur. J. Bio-
chem. 186, 123^128.
[19] Carling, D., Clarke, P.R., Zammit, V.A. and Hardie, D.G. (1989)
Eur. J. Biochem. 186, 129^136.
[20] Yao, S.Y.M., Ng, A.M.L., Muzyka, W.R., Gri⁄ths, M., Cass,
C.E., Baldwin, S.A. and Young, J.D. (1997) J. Biol. Chem. 272,
28423^28430.
[21] Cohen, P. (1997) Trends Cell Biol. 7, 353^361.
[22] Xi, X., Han, J. and Zhang, J.Z. (2001) J. Biol. Chem. 276, 41029^
41034.
[23] Huang, M., Wang, Y., Collins, M., Gu, J.J., Mitchell, B.S. and
Graves, L.M. (2002) J. Biol. Chem. 277, 28364^28367.
[24] Woods, A., Azzout-Marniche, D., Foretz, M., Stein, S., Lemarc-
hand, P., Ferre, P., Foufelle, F. and Carling, D. (2000) Mol. Cell.
Biol. 20, 6704^6711.
FEBS 26667 23-10-02
L.G.D. Fryer et al./FEBS Letters 531 (2002) 189^192192
